These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 11151804)

  • 1. Effects of endothelium/leukocytes/platelet interaction on myocardial ischemia--reperfusion injury.
    Habazettl H; Hanusch P; Kupatt C
    Z Kardiol; 2000; 89 Suppl 9():IX/92-5. PubMed ID: 11151804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. c7E3Fab reduces postischemic leukocyte-thrombocyte interaction mediated by fibrinogen. Implications for myocardial reperfusion injury.
    Kupatt C; Habazettl H; Hanusch P; Wichels R; Hahnel D; Becker BF; Boekstegers P
    Arterioscler Thromb Vasc Biol; 2000 Oct; 20(10):2226-32. PubMed ID: 11031208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardioprotective effects of abciximab (ReoPro) in an isolated perfused rat heart model of ischemia and reperfusion.
    Campbell B; Chuhran CM; Lefer DJ; Lefer AM
    Methods Find Exp Clin Pharmacol; 1999 Oct; 21(8):529-34. PubMed ID: 10599051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. c7E3 Fab inhibits low shear flow modulated platelet adhesion to endothelium and surface-absorbed fibrinogen by blocking platelet GP IIb/IIIa as well as endothelial vitronectin receptor--results from patients with acute myocardial infarction and healthy controls.
    Reininger AJ; Agneskirchner J; Bode PA; Spannagl M; Wurzinger LJ
    Thromb Haemost; 2000 Feb; 83(2):217-23. PubMed ID: 10739376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation.
    Straub A; Wendel HP; Azevedo R; Ziemer G
    Eur J Cardiothorac Surg; 2005 Apr; 27(4):617-21. PubMed ID: 15784360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracoronary formation and retention of micro aggregates of leukocytes and platelets contribute to postischemic myocardial dysfunction.
    Götz AK; Zahler S; Stumpf P; Welsch U; Becker BF
    Basic Res Cardiol; 2005 Sep; 100(5):413-21. PubMed ID: 15944806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New antiplatelet agents: platelet GPIIb/IIIa antagonists.
    Coller BS; Anderson K; Weisman HF
    Thromb Haemost; 1995 Jul; 74(1):302-8. PubMed ID: 8578476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine.
    Peter K; Kohler B; Straub A; Ruef J; Moser M; Nordt T; Olschewski M; Ohman ME; Kübler W; Bode C
    Circulation; 2000 Sep; 102(13):1490-6. PubMed ID: 11004138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction.
    Neumann FJ; Zohlnhöfer D; Fakhoury L; Ott I; Gawaz M; Schömig A
    J Am Coll Cardiol; 1999 Nov; 34(5):1420-6. PubMed ID: 10551687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical role of platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease.
    Lefkovits J; Topol EJ
    Cleve Clin J Med; 1996; 63(3):181-9. PubMed ID: 8665658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade.
    Ghaffari S; Kereiakes DJ; Lincoff AM; Kelly TA; Timmis GC; Kleiman NS; Ferguson JJ; Miller DP; Califf RA; Topol EJ
    Am J Cardiol; 1998 Jul; 82(1):7-12. PubMed ID: 9671000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
    Ibbotson T; McGavin JK; Goa KL
    Am J Cardiovasc Drugs; 2003; 3(5):381-6. PubMed ID: 14728074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction.
    Neumann FJ; Blasini R; Schmitt C; Alt E; Dirschinger J; Gawaz M; Kastrati A; Schömig A
    Circulation; 1998 Dec; 98(24):2695-701. PubMed ID: 9851955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonism of P2Y12 or GPIIb/IIIa receptors reduces platelet-mediated myocardial injury after ischaemia and reperfusion in isolated rat hearts.
    Barrabés JA; Inserte J; Mirabet M; Quiroga A; Hernando V; Figueras J; Garcia-Dorado D
    Thromb Haemost; 2010 Jul; 104(1):128-35. PubMed ID: 20431845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
    Schneider DJ; Taatjes DJ; Sobel BE
    Cardiovasc Res; 2000 Jan; 45(2):437-46. PubMed ID: 10728364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disparate effects of adhesion and degranulation of platelets on myocardial and coronary function in postischaemic hearts.
    Heindl B; Zahler S; Welsch U; Becker BF
    Cardiovasc Res; 1998 May; 38(2):383-94. PubMed ID: 9709399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms of platelet-mediated leukocyte recruitment during myocardial reperfusion.
    Kupatt C; Wichels R; Horstkotte J; Krombach F; Habazettl H; Boekstegers P
    J Leukoc Biol; 2002 Sep; 72(3):455-61. PubMed ID: 12223512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Platelet-leukocyte interactions in coronary heart disease: pathophysiology, clinical relevance, pharmacological modulation].
    Hézard N; Metz D; Garnotel R; Droullé C; Potron G; Nguyen P
    J Mal Vasc; 2000 Dec; 25(5):343-348. PubMed ID: 11148396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.